+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-05-17Number of Pages: 71

Exocrine Pancreatic Insufficiency Market (Therapeutic - Pancreatic Enzyme Replacement Therapy (Creon, Zenpep, Pancreaze, Ultresa, Viokase, Pertzye) and Phase III Drugs; Diagnostic Test - Blood Tests, Endoscopic Ultra-sonography, MRI, and CT Scanning) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 - 2023

Table of Content

1. Preface
    1.1. Report Description
    1.2. Market Segmentation
    1.3. Research Methodology
    1.4. Assumptions

2. Executive Summary
    2.1. Market Snapshot: Exocrine Pancreatic Insufficiency, 2014 & 2023
    2.2. Comparative Analysis: Exocrine Pancreatic Insufficiency Market, by Geography (%), 2014 & 2023 
    2.3. U.S. Exocrine Pancreatic Insufficiency Market, by Type, 2014 (US$ Mn)

3. Exocrine Pancreatic Insufficiency Market – Industry Analysis
    3.1. Introduction and Market Definition
    3.2. Treatment other than Drug therapy
    3.3. Market Dynamics
    3.4. Market Attractiveness Analysis of Global Exocrine Pancreatic Insufficiency Market, by Geography
    3.5. Impact Analysis
    3.6. Pipeline Analysis (Phase II and I) Tabular Presentation
    3.7. Competitive Analysis 

4. Global Exocrine Pancreatic Insufficiency Market– By Therapeutics 2013-2023 (US$ Mn)
    4.1. Overview
    4.2. Pancreatic Enzyme Replacement Therapy (PERT) Drugs
          4.2.1. Creon
          4.2.2. Zenpep
          4.2.3. Pancreaze
          4.2.4. Ultresa
          4.2.5. Viokace
          4.2.6. Pertzye
    4.3. Exocrine Pancreatic Insufficiency Drugs, Pipeline Analysis, Post launch - 2023, Sollpura (Liprotamase)

5. Global Exocrine Pancreatic Insufficiency Market – By Diagnostic Tests
    5.1. Overview
    5.2. Blood Tests
    5.3. Endoscopic Ultra-Sonography (EUS)
    5.4. Magnetic Resonance Imaging (MRI)
    5.5. CT Scanning

6. Global Exocrine Pancreatic Insufficiency Market – By Geography
    6.1. North America
          6.1.1. U.S.
          6.1.2. Canada
          6.1.3. Rest of North America
    6.2. Europe
          6.2.1. U.K.
          6.2.2. Germany
          6.2.3. Rest of Europe
    6.3. Asia Pacific
          6.3.1. China
          6.3.2. Japan
          6.3.3. Rest of APAC
    6.4. Latin America
          6.4.1. Brazil
          6.4.2. Mexico
          6.4.3. Rest of LATAM
    6.5. Rest of the World
          6.5.1. South Africa
          6.5.2. Russia
          6.5.3. Rest of RoW

7. Company Profiles
    7.1. Abbvie Inc.
    7.2. Allergan plc.
    7.3. Nordmark Arzneimittel GmbH & Co. KG 
    7.4. Digestive Care, Inc.
    7.5. Cilian AG 
    7.6. Anthera Pharmaceuticals Inc.
    7.7. Janssen Pharmaceuticals Inc. 
    7.8. AzurRx BioPharma, Inc.

List of Figures

FIG. 1 Market Segmentation
FIG. 2 Global Exocrine Pancreatic Insufficiency (EPI) Market Share, by Geography, 2014 
FIG. 3 Global Exocrine Pancreatic Insufficiency (EPI) Market Share, by Geography, 2023
FIG. 4 Exocrine Pancreatic Insufficiency (EPI) Market, by Type, 2014 (US$ Mn)
FIG. 5 Global Exocrine Pancreatic Insufficiency Market, by Geography, Value (%), 2014
FIG. 6 U.S. Exocrine Pancreatic Insufficiency Market, by Key Players, 2014 (%)
FIG. 7 U.S. Creon Market Revenue, (US$ Mn), 2013–2023
FIG. 8 U.S. Zenpep Market Revenue, (US$ Mn), 2013–2023
FIG. 9 U.S. Pancreaze Market Revenue, (US$ Mn), 2013–2023
FIG. 10 U.S. Ultresa Market Revenue, (US$ Mn), 2013–2023
FIG. 11 U.S. Viokace Market Revenue, (US$ Mn), 2013–2023
FIG. 12 U.S Pertzye Market Revenue, (US$ Mn), 2013–2023
FIG. 13 U.S Sollpura (Liprotamase) Market Revenue, (US$ Mn), 2013–2023
FIG. 14 Global Blood Tests Market Revenue, (US$ Mn), 2013–2023
FIG. 15 Global Endoscopic ultra-sonography (EUS) Market Revenue, (US$ Mn), 2013–2023
FIG. 16 Global Magnetic resonance imaging (MRI) Market Revenue, (US$ Mn), 2013–2023
FIG. 17 Global CT scanning Market Revenue, (US$ Mn), 2013–2023
FIG. 18 AbbVie, Inc., Annual Revenue, 2013–2015 (US$ Mn)
FIG. 19 Allergan plc Annual Revenue, 2012–2014 (US$ Mn)

List of Tables

TABLE 1 Exocrine Pancreatic Insufficiency (EPI): Market Snapshot 
TABLE 2 Impact Analysis
TABLE 3 Pipeline Analysis (Phase I and II): Tabular Presentation
TABLE 4 U.S. Exocrine Pancreatic Insufficiency (EPI) Market Revenue, (US$ Mn), 2013–2023
TABLE 5 Global Exocrine Pancreatic Insufficiency Market Revenue, by Diagnostic Test, (US$ Mn), 2013–2023
TABLE 6 Global Exocrine Pancreatic Insufficiency Market Revenue, by Geography, 2013–2023
TABLE 7 North America Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023
TABLE 8 Europe Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023
TABLE 9 Asia Pacific Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023
TABLE 10 Latin America Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023
TABLE 11 Rest of the World (RoW) Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013–2023


 
 
Back To Top